Protective lipid deficiency

Diabetes creates a functionally limiting shortage or inappropriate composition of protective membrane lipids or lipid-derived maintenance signals, and correcting that deficit would materially preserve human peptidergic C-fibers.

Scope: Default early type 2 DPN. This is a lipid-composition/availability hypothesis, including deficient conversion or incorporation of essential fatty-acid derivatives. It is not the claim that every person with diabetes lacks dietary fat.

Causal role: loss of protective substrate or signaling support. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint.

Source assessment

Base judgment: 11.6%; skeptical–optimistic sensitivity: 0.7%–43.4%. Subjective probabilities of the causal proposition below, not effect sizes. Decimal places only show arithmetic. Reviewed 13 September 2026. Probability method · Collection index.

Reasoning from the biological requirements

Total lipid abundance does not determine whether a cell has the right lipids in the right membrane. Specific fatty-acid products can contribute to membrane properties or become mediators that influence vascular, immune and repair functions. For a deficiency to cause damage, the relevant product must actually become limiting under diabetic conditions; other lipids or pathways must fail to compensate; and restoring the missing physiological function must preserve the axon. A supplement can have a pharmacological effect without showing that a natural deficiency caused disease.

Probabilities of the necessary claims

Conditional prices are skeptical / base / optimistic. Each price after the first assumes all earlier requirements are true. Their order is an order for assessing joint belief, not necessarily a linear biological pathway. The cumulative column uses the base scenario. Temporal order, connected compartments and the causal prevention comparison are included in these requirements, without extra generic multipliers.

See the claims and probabilities table above.

R1

Conversion and composition changes are plausible, but direct measurements at the relevant human membrane or signaling site are limited.

R2

A shifted lipid profile can be adaptive or a consequence of injury rather than a deficiency.

R3

These are alternative routes; evidence for function is stronger than for selective peptidergic structural loss.

R4

Clinical supplementation results support possibility but do not establish the causal deficit or subtype-specific prevention.

Evidence that moves the judgment

• A randomized, double-blind study enrolled 111 people with mild diabetic neuropathy across seven centers and compared gamma-linolenic acid, 480 mg/day, with placebo for one year. Changes favored treatment on 16 functional/clinical parameters, with 13 reported significant. These correlated outcomes were not peptidergic axon counts, and treatment benefit does not identify a pre-existing GLA deficit. Keen et al., 1993.

• A human omega-3 supplementation study associated metabolic-pathway changes with improved painful DPN. Its metabolomic and symptom observations do not establish that deficient protective lipids caused structural loss. 2022 primary study.

• Schwann-cell mitochondrial disruption in a genetic mouse model altered lipid metabolism and caused axonal degeneration. This establishes that support-cell lipid handling can matter, but it is not a demonstration of a specific essential-fatty-acid deficit in ordinary human diabetes. Viader et al., 2013.

Why these odds and how uncertain they are

The human randomized GLA result gives this more support than a pathway-enrichment-only proposal, while its endpoints and broad intervention leave the key causal distinction unresolved. I price a naturally limiting protective-lipid deficit, not merely the possibility that adding a bioactive lipid can improve symptoms. That stricter requirement, and the absence of an identified human terminal lipid pool, keep the complete probability modest.

The skeptical scenario interprets lipid changes as consequences or adaptive remodeling and supplement effects as pharmacology. The optimistic scenario assumes a reproducible subgroup with impaired conversion/incorporation and limited compensation. Different protective lipid species need not have the same cause or effect; the union is broader than a claim about one enzyme, and the current evidence cannot supply precise odds for every individual lipid.

Conditional inputs: base [65, 55, 65, 50]%; skeptical [30, 25, 35, 25]%; optimistic [85, 80, 85, 75]%. Products give the headline prices. The span measures sensitivity to these interpretations; it is not a statistical confidence interval.

Numerical update example: Public human nerve lipid measurements linked to a specific lost function and preserved terminals after correction would strengthen requirement 2. Demonstrating adequate product availability and normal function despite the altered lipid profile would weaken it. Changing only requirement 2 from 55% to 85% raises the whole price to 18.0%; reducing it to 20% lowers the price to 4.2%. These are hypothetical evidence updates. Even resolving that one requirement with certainty would leave a complete price of 21.1% if the others stayed unchanged.

Overlap and boundary

Distinct from excess fatty-acid delivery, toxic deoxysphingolipids and ceramides. Can operate through Schwann support or skin repair. Saturated/unsaturated balance is a causal composition question, not a rule that all lipids in either category share a sign.